Equity
DexCom, Inc. (DXCM) perpetual futures
DexCom, Inc. is a US medical technology company that develops and markets continuous glucose monitoring (CGM) systems, including Dexcom G6, Dexcom ONE, Dexcom Share and the Dexcom Real-Time API, for people with diabetes and healthcare practitioners.
Price chart
Interactive TradingView chart
TradingView symbol NASDAQ:DXCM
Loads TradingView's third-party widget (about 1 MB) on demand.
Trading data
Perpetual market activity
0/0 live markets
Trading data
Perpetual market activity
Spot performance
Venue matrix
0 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
| Trade |
|---|
Best venues for this underlying
Best liquidity
-Tightest spread
-Highest volume
-Company data
Company fundamentals
Updated 2h ago
Company data
Company fundamentals
More metrics
Fundamental detail
Annual + quarterlyRefreshed 2h ago
Charts: revenue, profit, cash flow & valuation
Next catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsRevenue mix
PendingAnalysts
PendingOwnership
DXCM-PERPFilings
PendingTranscripts
PendingCompany news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.No articles from Reuters, WSJ, Bloomberg or FT for this company in our feed.
Analyst track record
How the analysts covering DXCM have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 156 | 453 |
| Analysts | 33 | 36 |
| Buy / hold / sell | 142 / 11 / 3 | 410 / 40 / 3 |
| Upgrades / downgrades / initiations | 1 / 0 / 4 | 4 / 3 / 11 |
| Price targets hit / missed | 84 / 56 (60%) | 108 / 311 (26%) |
| Avg. return after a rating (TipRanks) | +0.9% | -13.0% |
| Best / worst call | +37.5% / -22.7% | +37.5% / -49.1% |
After buy calls on this stock: median 21-day move +2.2% vs S&P 500 +1.2% (n = 409)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- William PlovanicCanaccord Genuity47% hit rate on this stock · 17 targets measuredBuytarget $90.00Aug 3, 2026
- Mike KratkyLeerink Partners44% hit rate on this stock · 18 targets measuredBuytarget $84.00Oct 14, 2025
- Travis SteedBank of America Securities43% hit rate on this stock · 14 targets measuredBuyno targetJul 31, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Sep 23, 2026 | Richard NewitterTruist Financial | BuyMaintained | $102 | article ↗ |
| Sep 18, 2026 | Richard NewitterTruist Financial | BuyReiterated | $102 | article ↗ |
| Sep 18, 2026 | Josh JenningsTD Cowen | BuyMaintained | $95.00 | article ↗ |
| Sep 9, 2026 | Larry BiegelsenWells Fargo | BuyMaintained | $90.00 | article ↗ |
| Aug 14, 2026 | Joanne WuenschCiti | BuyMaintained | $105 | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data via FMP · computed Sep 27, 2026 · 156 ratings